It happens when your MM no longer responds to the treatment you’re taking. Over time, many people with MM will go through periods of response to treatment and periods of relapse. To find out how your disease is progressing, your doctor will monitor the levels of M protein in your blood. A large increase in this protein, or M spike, can indicate a relapse.
When a relapse occurs, it’s important to understand your options. POMALYST is a treatment option that’s proven to help fight myeloma progression after relapse on REVLIMID® (lenalidomide) and a proteasome inhibitor (PI).
POMALYST is a prescription medicine, taken along with the medicine dexamethasone, used to treat people with multiple myeloma who have previously received at least 2 medicines to treat multiple myeloma, including a proteasome inhibitor and lenalidomide, and whose disease has become worse during treatment or within 60 days of finishing the last treatment. It is not known if POMALYST is safe and effective in children. POMALYST is only available through a restricted distribution program, POMALYST REMS®.
WARNINGS: Risk to unborn babies, and blood clots.
Before you begin taking POMALYST, you must read and agree to all of the instructions in the POMALYST REMS® program. Before prescribing POMALYST, your healthcare provider (HCP) will explain the POMALYST REMS program to you and have you sign the Patient-Physician Agreement Form.
POMALYST can cause serious side effects, including:
Call your healthcare provider or get medical help right away if you get any of the following during treatment with POMALYST:
Get emergency medical help right away if you develop any of the following signs or symptoms during treatment with POMALYST:
Do not take POMALYST if you:
Take POMALYST exactly as prescribed and follow all the instructions of the POMALYST REMS program.
Your doctor may repeat certain tests to make sure your results are accurate. If your MM has come back, you and your healthcare team will discuss available treatment options and decide on what’s best for you.
A “response” means a lower number of myeloma cells or M protein in your body as a result of treatment. Response types generally differ by degree or levels. Talk to your healthcare team about how they determine response.
A relapse can happen months or years after your initial treatment. MM relapse can cause worse symptoms than when the cancer first appeared. Worse symptoms can be a sign of a more aggressive cancer. Most people with MM can expect to have a relapse.
For patients with standard-risk disease, the first period of response can last 2-3 years or even longer.
People may experience these signs and symptoms of MM:
It’s a good idea to talk to your doctor about treatment goals in the event of a relapse. Your doctor will help explain what relapse is, discuss different options and decide which treatment or combination of treatments will be most appropriate for you.
Ask your doctor about pomalidomide (POMALYST). It’s proven to help fight myeloma progression at relapse and is part of a treatment regimen that’s recommended by the National Comprehensive Cancer Network® (NCCN®).*1
You’ll find several resources and tools to support you and your caregiver on the POMALYST Patient Resources page. This page includes links to educational and patient videos, organizations for patients and caregivers, and brochures that cover almost every aspect of treatment.
IMiD, immunomodulatory drug; M protein, monoclonal protein; MM, multiple myeloma; PI, proteasome inhibitor.
Reference: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.3.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed February 15, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.